Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial

波生坦 医学 安慰剂 肺动脉高压 内科学 双盲 心脏病学 随机对照试验 内皮素受体 替代医学 受体 病理
作者
Nazzareno Galiè,LJ Rubin,Marius M. Hoeper,Pavel Jansa,Hikmet Al‐Hiti,Gisela Martina Bohns Meyer,Eleonora Chiossi,Andjela Kusic‐Pajic,Gérald Simonneau
出处
期刊:The Lancet [Elsevier BV]
卷期号:371 (9630): 2093-2100 被引量:1006
标识
DOI:10.1016/s0140-6736(08)60919-8
摘要

Background Treatments for pulmonary arterial hypertension have been mainly studied in patients with advanced disease (WHO functional class [FC] III and IV). This study was designed to assess the effect of the dual endothelin receptor antagonist bosentan in patients with WHO FC II pulmonary arterial hypertension. Methods Patients with WHO FC II pulmonary arterial hypertension aged 12 years or over with 6-min walk distance of less than 80% of the normal predicted value or less than 500 m associated with a Borg dyspnoea index of 2 or greater were enrolled in this double-blind, placebo-controlled, multicentre trial. 185 patients were randomly assigned to receive bosentan (n=93) or placebo (n=92) for the 6-month double-blind treatment period via a centralised integrated voice recognition system. Primary endpoints were pulmonary vascular resistance at month 6 expressed as percentage of baseline and change from baseline to month 6 in 6-min walk distance. Analyses of the primary endpoints were done with all randomised patients who had a valid baseline assessment and an assessment or an imputed value for month 6. This trial was registered with ClinicalTrials.gov, number NCT00091715. Findings Analyses were done with 168 patients (80 in the bosentan group, 88 in the placebo group) for pulmonary vascular resistance and with 177 (86 and 91) for 6-min walking distance. At month 6, geometric mean pulmonary vascular resistance was 83·2% (95% CI 73·8–93·7) of the baseline value in the bosentan group and 107·5% (97·6–118·4) of the baseline value in the placebo group (treatment effect −22·6%, 95% CI −33·5 to −10·0; p<0·0001). Mean 6-min walk distance increased from baseline in the bosentan group (11·2 m, 95% CI −4·6 to 27·0) and decreased in the placebo group (−7·9 m, −24·3 to 8·5), with a mean treatment effect of 19·1 m (95% CI 3·6–41·8; p=0·0758). 12 (13%) patients in the bosentan group and eight (9%) in the placebo group reported serious adverse events, the most common of which were syncope in the bosentan group and right ventricular failure in the placebo group. Interpretation Bosentan treatment could be beneficial for patients with WHO FC II pulmonary arterial hypertension. Funding Actelion Pharmaceuticals Ltd.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
iceanbecky发布了新的文献求助30
2秒前
Caboda发布了新的文献求助10
3秒前
要减肥发布了新的文献求助10
3秒前
zz发布了新的文献求助10
3秒前
wanghongyue完成签到,获得积分10
3秒前
二十一日完成签到,获得积分10
4秒前
CodeCraft的应助被洁净的千凡采纳,获得10
4秒前
GBY发布了新的文献求助10
4秒前
baiying发布了新的文献求助10
5秒前
澍归发布了新的文献求助10
5秒前
7秒前
syvshc的应助被369ninja采纳,获得10
8秒前
8秒前
8秒前
8秒前
9秒前
qqqqq完成签到,获得积分20
9秒前
呆萌的青烟完成签到,获得积分10
10秒前
Ditf发布了新的文献求助10
11秒前
斯文钢笔发布了新的文献求助10
13秒前
爱撒娇的天磊完成签到,获得积分10
13秒前
菠菠完成签到,获得积分20
13秒前
水煮电吹风的应助被suhang2024采纳,获得10
14秒前
酷炫蛋挞发布了新的文献求助10
14秒前
乔清发布了新的文献求助30
14秒前
天天开心完成签到,获得积分10
15秒前
鲸鱼完成签到 ,获得积分10
15秒前
希望天下0贩的0的应助被zzzz采纳,获得10
15秒前
16秒前
17秒前
Mimo发布了新的文献求助10
17秒前
18秒前
慕青的应助被小王小王采纳,获得10
18秒前
19秒前
斯文钢笔完成签到,获得积分10
20秒前
xushanqi发布了新的文献求助10
21秒前
隐形曼青的应助被GBY采纳,获得10
21秒前
21秒前
xing_xing的应助被好运莲莲采纳,获得20
22秒前
追寻嵩发布了新的文献求助10
22秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8177849
求助须知:如何正确求助?哪些是违规求助? 9568641
关于积分的说明 21800145
捐赠科研通 7772473
什么是DOI,文献DOI怎么找? 3432537
关于科研通互助平台的介绍 2556720
邀请新用户注册赠送积分活动 2478067